[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EE05453B1 - Protsess asetidinoonvahehendite valmistamiseks - Google Patents

Protsess asetidinoonvahehendite valmistamiseks

Info

Publication number
EE05453B1
EE05453B1 EEP200300464A EEP200300464A EE05453B1 EE 05453 B1 EE05453 B1 EE 05453B1 EE P200300464 A EEP200300464 A EE P200300464A EE P200300464 A EEP200300464 A EE P200300464A EE 05453 B1 EE05453 B1 EE 05453B1
Authority
EE
Estonia
Prior art keywords
preparation
azetidinone intermediates
compound
azetidinone
intermediates
Prior art date
Application number
EEP200300464A
Other languages
English (en)
Estonian (et)
Inventor
Fu Xiaoyong
L. Mcallister Timothy
K. Thiruvengadam T.
Tann Chou-Hong
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of EE200300464A publication Critical patent/EE200300464A/xx
Publication of EE05453B1 publication Critical patent/EE05453B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EEP200300464A 2001-03-28 2002-03-25 Protsess asetidinoonvahehendite valmistamiseks EE05453B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27928801P 2001-03-28 2001-03-28
PCT/US2002/009123 WO2002079174A2 (en) 2001-03-28 2002-03-25 Enantioselective synthesis of azetidinone intermediate compounds

Publications (2)

Publication Number Publication Date
EE200300464A EE200300464A (et) 2003-12-15
EE05453B1 true EE05453B1 (et) 2011-08-15

Family

ID=23068350

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300464A EE05453B1 (et) 2001-03-28 2002-03-25 Protsess asetidinoonvahehendite valmistamiseks

Country Status (28)

Country Link
US (1) US6627757B2 (pt)
EP (1) EP1373230B1 (pt)
JP (1) JP4145663B2 (pt)
KR (1) KR100590342B1 (pt)
CN (1) CN1275949C (pt)
AT (1) ATE305459T1 (pt)
AU (1) AU2002258605B2 (pt)
BG (1) BG66189B1 (pt)
BR (1) BRPI0208384B1 (pt)
CA (1) CA2442219C (pt)
CZ (1) CZ304929B6 (pt)
DE (1) DE60206365T2 (pt)
DK (1) DK1373230T3 (pt)
EA (1) EA006898B1 (pt)
EE (1) EE05453B1 (pt)
ES (1) ES2245733T3 (pt)
HR (1) HRP20030760B1 (pt)
HU (1) HU230229B1 (pt)
IL (2) IL157552A0 (pt)
MX (1) MXPA03008803A (pt)
NZ (1) NZ527852A (pt)
PL (1) PL205952B1 (pt)
RS (1) RS50386B (pt)
SI (1) SI1373230T1 (pt)
SK (1) SK287408B6 (pt)
UA (1) UA75644C2 (pt)
WO (1) WO2002079174A2 (pt)
ZA (1) ZA200306612B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
EP1699759B1 (en) 2003-12-23 2010-10-20 AstraZeneca AB Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
WO2005069900A2 (en) * 2004-01-16 2005-08-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
US20060069080A1 (en) * 2004-09-29 2006-03-30 Veltri Enrico P Combinations of substituted azetidinones and CB1 antagonists
EP1819684B1 (en) 2004-12-03 2013-08-07 Intervet International B.V. Substituted piperazines as cb1 antagonists
US8308559B2 (en) * 2007-05-07 2012-11-13 Jay Chun Paradise box gaming system
TW200726746A (en) 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
EP1885378A4 (en) * 2005-05-09 2010-10-27 Microbia Inc METAL ORGANIC BENZOLE PHOSPHONATE COUPLING AGENTS
MX2007014172A (es) * 2005-05-11 2008-04-02 Microbia Inc Procedimiento para la produccion de 4-bifenililacetidina-2-onas fenolicos.
CA2609506A1 (en) * 2005-05-25 2006-11-30 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
US7635705B2 (en) * 2005-06-20 2009-12-22 Schering Corporation Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
JP2008517951A (ja) * 2005-09-08 2008-05-29 テバ ファーマシューティカル インダストリーズ リミティド （３ｒ，４ｓ）−４−（（４−ベンジルオキシ）フェニル）−１−（４−フルオロフェニル）−３−（（ｓ）−３−（４−フルオロフェニル）−３−ヒドロキシプロピル）−２−アゼチジノン、すなわちエゼチミベの合成のための中間体の調製方法
HUP0501164A2 (en) * 2005-12-20 2007-07-30 Richter Gedeon Nyrt New industrial process for the production of ezetimibe
MX2008009354A (es) 2006-01-18 2008-09-30 Schering Corp Moduladores de receptores cannabinoides.
KR101074968B1 (ko) * 2006-02-16 2011-10-18 고토부키 세이야쿠 가부시키가이샤 광학활성 알코올을 제조하는 방법
US7910698B2 (en) 2006-02-24 2011-03-22 Schering Corporation NPC1L1 orthologues
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
WO2008030382A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
JP2010529148A (ja) * 2007-06-07 2010-08-26 テバ ファーマシューティカル インダストリーズ リミティド エゼチミブ製造のための還元方法
NZ582249A (en) * 2007-06-28 2012-06-29 Intervet Int Bv Substituted piperazines as cb1 antagonists
WO2009005671A2 (en) * 2007-06-28 2009-01-08 Schering Corporation Substituted piperazines as cb1 antagonists
WO2009032264A1 (en) * 2007-08-30 2009-03-12 Teva Pharmaceutical Industries Ltd. Processes for preparing intermediates of ezetimibe by microbial reduction
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
US8273554B2 (en) 2008-08-29 2012-09-25 Codexis, Inc. Ketoreductase polypeptides for the stereoselective production of (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one
CA2757722C (en) 2009-04-01 2018-05-22 Matrix Laboratories Ltd. Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
EP2467473B1 (en) 2009-08-19 2016-03-23 Codexis, Inc. Ketoreductase polypeptides for the preparation of phenylephrine
EP2566497B1 (en) 2010-05-04 2015-07-29 Codexis, Inc. Biocatalysts for ezetimibe synthesis
WO2012155932A1 (en) 2011-05-17 2012-11-22 Pharmathen S.A. Improved process for the preparation of ezetimibe
CN111518046B (zh) * 2020-06-04 2022-04-15 中山奕安泰医药科技有限公司 依泽替米贝中间体及依泽替米贝的制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2046823A1 (de) 1970-09-23 1972-03-30 Farbwerke Hoechst AG vormals Meister Lucius & Brüning, 6000 Frankfurt Neue Azetidinone-(2) und Verfahren zu deren Herstellung
JPS5628057A (en) 1979-08-13 1981-03-19 Isuzu Motors Ltd Front cab suspension device for tiltable cab
DE3006193C2 (de) 1980-02-19 1984-04-12 Siemens AG, 1000 Berlin und 8000 München Elektrische Anschlußverbindung der Elektroden eines Gasentladungs-Überspannungsableiters
US4680391A (en) 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
JPS61121479A (ja) 1984-11-19 1986-06-09 Mitsubishi Electric Corp 太陽電池素子
JPS61180212A (ja) 1985-02-06 1986-08-12 Asahi Optical Co Ltd 後絞り型写真レンズ
JPS62219681A (ja) 1986-03-20 1987-09-26 Toshiba Corp 光信号処理素子の基準光源
ZA877398B (en) 1986-10-03 1989-05-30 Lilly Co Eli 7-((meta-substituted)phenylglycine)1-carba-1-dethiacephalosporins
US4803266A (en) 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
EP0333268A1 (en) 1988-03-18 1989-09-20 Merck & Co. Inc. Process for synthesis of a chiral 3-beta hydrogen (3R) 4-aroyloxy azetidinone
IL89835A0 (en) 1988-04-11 1989-12-15 Merck & Co Inc Substituted azetidinones,their preparation and pharmaceutical compositions containing them
US4952689A (en) 1988-10-20 1990-08-28 Taisho Pharmaceutical Co., Ltd. 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
US4876365A (en) 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
FR2640621B1 (fr) 1988-12-19 1992-10-30 Centre Nat Rech Scient N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
US4983597A (en) 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
IL99658A0 (en) 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
JPH04356195A (ja) 1991-05-30 1992-12-09 Kyowa Hakko Kogyo Co Ltd アゼチジノン誘導体の製造法
US5561227A (en) 1991-07-23 1996-10-01 Schering Corporation Process for the stereospecific synthesis of azetidinones
US5688785A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5688787A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
ES2107548T3 (es) 1991-07-23 1997-12-01 Schering Corp Compuestos de beta-lactama sustituidos utiles como agentes hipocolesterolemicos y procedimientos para su preparacion.
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
CZ7696A3 (en) 1993-07-09 1996-04-17 Schering Corp Process for preparing azetidinone
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5631635A (en) * 1995-05-08 1997-05-20 Motorola, Inc. Message/response tracking system and method for a two-way selective call receiving device
US5618707A (en) 1996-01-04 1997-04-08 Schering Corporation Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof
CA2235943C (en) 1995-10-31 2002-10-01 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
WO1997016424A1 (en) 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
WO1997021676A1 (en) 1995-12-08 1997-06-19 Smithkline Beecham Plc Azetidinone compounds for the treatment of atherosclerosis
AU2698697A (en) 1996-04-26 1997-11-19 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5886171A (en) 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
GB9611947D0 (en) 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
AU3667297A (en) 1996-07-09 1998-02-02 Merck & Co., Inc. Therapy for combined hyperlipidemia
AU4050797A (en) 1996-08-02 1998-02-25 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
AU722289B2 (en) 1996-10-01 2000-07-27 Aptalis Pharmatech, Inc. Taste-masked microcapsule compositions and methods of manufacture
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
CA2301543C (en) 1997-10-07 2005-05-17 Boehringer Ingelheim (Canada) Ltd. Azetidinone derivatives for the treatment of hcmv infections
US6133001A (en) 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
AU2030100A (en) 1998-12-07 2000-06-26 Schering Corporation Process for the synthesis of azetidinones
US6207822B1 (en) * 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
EP1169468B1 (en) 1999-04-05 2012-03-14 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(r)-¬3(s)-hydroxy-3-(4-fluorophenyl)propyl) -4(s)-(4-hydroxyphenyl)-2-azetidinone
AU4343500A (en) 1999-04-16 2000-11-02 Schering Corporation Use of azetidinone compounds
DK1347987T3 (da) 2000-12-20 2005-01-31 Schering Corp Sukkersubstituerede 2-azetidinoner, der er anvendelige som hypocholesterolæmiske midler
RS50864B (sr) 2000-12-21 2010-08-31 Sanofi-Aventis Deutschland Gmbh. Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same

Also Published As

Publication number Publication date
BG108168A (en) 2004-09-30
BRPI0208384B1 (pt) 2016-05-31
IL157552A (en) 2009-08-03
KR20030085573A (ko) 2003-11-05
YU74803A (sh) 2006-05-25
ES2245733T3 (es) 2006-01-16
SK11862003A3 (sk) 2004-04-06
CA2442219A1 (en) 2002-10-10
EA200300970A1 (ru) 2004-04-29
DE60206365D1 (de) 2005-11-03
BR0208384A (pt) 2004-06-15
HUP0303526A3 (en) 2004-11-29
EP1373230A2 (en) 2004-01-02
ATE305459T1 (de) 2005-10-15
CN1500083A (zh) 2004-05-26
BG66189B1 (bg) 2011-12-30
KR100590342B1 (ko) 2006-06-15
JP4145663B2 (ja) 2008-09-03
HK1057546A1 (en) 2004-04-08
SK287408B6 (sk) 2010-09-07
RS50386B (sr) 2009-12-31
UA75644C2 (en) 2006-05-15
WO2002079174A3 (en) 2003-02-27
PL205952B1 (pl) 2010-06-30
WO2002079174A2 (en) 2002-10-10
IL157552A0 (en) 2004-03-28
SI1373230T1 (sl) 2005-12-31
US20020193607A1 (en) 2002-12-19
CZ20032610A3 (en) 2004-03-17
US6627757B2 (en) 2003-09-30
JP2004532210A (ja) 2004-10-21
CN1275949C (zh) 2006-09-20
HRP20030760A2 (en) 2004-08-31
CZ304929B6 (cs) 2015-01-28
MXPA03008803A (es) 2004-02-18
EA006898B1 (ru) 2006-04-28
EP1373230B1 (en) 2005-09-28
EE200300464A (et) 2003-12-15
HRP20030760B1 (hr) 2011-07-31
HUP0303526A2 (hu) 2004-01-28
DE60206365T2 (de) 2006-07-06
HU230229B1 (hu) 2015-10-28
ZA200306612B (en) 2004-10-12
CA2442219C (en) 2007-09-11
NZ527852A (en) 2005-03-24
DK1373230T3 (da) 2005-11-07
AU2002258605B2 (en) 2006-01-12
PL363864A1 (en) 2004-11-29

Similar Documents

Publication Publication Date Title
EE05453B1 (et) Protsess asetidinoonvahehendite valmistamiseks
MXPA04001323A (es) Dihidro-3-halo-1h-pirazol-5-carboxilatos sustituidos, su preparacion y uso.
DE69831868D1 (en) Antithrombosemittel
ATE297203T1 (de) Antithrombotische mitteln
NZ514711A (en) Compounds useful as anti-inflammatory agents
BG106340A (en) Substituted oxoazaheterocyclyl compounds
IL173377A0 (en) Compounds for the treatment of metabolic disorders
AU2001280438A1 (en) Substituted heterocyclic amides
GB0127903D0 (en) Improvements relating to organic compounds
MY138263A (en) Therapeutic chroman compounds
AU2001284190A1 (en) Benzylidene thiazolidinediones and their use as antimycotic agents
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
DE60114640D1 (en) Antithrombosemittel
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
MXPA03002493A (es) Proceso eficiente para preparacion de un inhibidor del factor xa.
IL156768A0 (en) Process for preparing (+/-) trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine
ATE419238T1 (de) Arylsulfanyl und heteroarylsulfanyl-derivate zur behandlung von schmerz
DE60043228D1 (de) Herstellungsverfahren von 2-cyanopyridinen
YU62302A (sh) Postupak za izradu jedinjenja 2-(4-alkil-1-piperazinil)- benzaldehida i benzilidenila
SE0103646D0 (sv) Therapeutic chroman compounds

Legal Events

Date Code Title Description
HC1A Change of owner name
HC1A Change of owner name